This assay is useful to provide an estimate of prognosis (aggressiveness of disease) of B-cell chronic lymphocytic leukemia (B-CLL)and to help evaluate treatment options B-CLL with mutated IgVH is typically less aggressive (more slowly progressive) than B-CLL with unmutated IgVH